|
|
|
|
LEADER |
02650nam a2200349Ia 4500 |
001 |
10.1111-biom.13360 |
008 |
220427s2021 CNT 000 0 und d |
020 |
|
|
|a 0006341X (ISSN)
|
245 |
1 |
0 |
|a Estimation of conditional power for cluster-randomized trials with interval-censored endpoints
|
260 |
|
0 |
|b John Wiley and Sons Inc
|c 2021
|
856 |
|
|
|z View Fulltext in Publisher
|u https://doi.org/10.1111/biom.13360
|
520 |
3 |
|
|a Cluster-randomized trials (CRTs) of infectious disease preventions often yield correlated, interval-censored data: dependencies may exist between observations from the same cluster, and event occurrence may be assessed only at intermittent study visits. This data structure must be accounted for when conducting interim monitoring and futility assessment for CRTs. In this article, we propose a flexible framework for conditional power estimation when outcomes are correlated and interval-censored. Under the assumption that the survival times follow a shared frailty model, we first characterize the correspondence between the marginal and cluster-conditional survival functions, and then use this relationship to semiparametrically estimate the cluster-specific survival distributions from the available interim data. We incorporate assumptions about changes to the event process over the remainder of the trial—as well as estimates of the dependency among observations in the same cluster—to extend these survival curves through the end of the study. Based on these projected survival functions, we generate correlated interval-censored observations, and then calculate the conditional power as the proportion of times (across multiple full-data generation steps) that the null hypothesis of no treatment effect is rejected. We evaluate the performance of the proposed method through extensive simulation studies, and illustrate its use on a large cluster-randomized HIV prevention trial. © 2020 The International Biometric Society
|
650 |
0 |
4 |
|a cluster-randomized trial
|
650 |
0 |
4 |
|a computer simulation
|
650 |
0 |
4 |
|a Computer Simulation
|
650 |
0 |
4 |
|a conditional power
|
650 |
0 |
4 |
|a correlation
|
650 |
0 |
4 |
|a estimation method
|
650 |
0 |
4 |
|a human immunodeficiency virus
|
650 |
0 |
4 |
|a infectious disease
|
650 |
0 |
4 |
|a interim monitoring
|
650 |
0 |
4 |
|a interval censoring
|
650 |
0 |
4 |
|a methodology
|
650 |
0 |
4 |
|a parameterization
|
650 |
0 |
4 |
|a performance assessment
|
650 |
0 |
4 |
|a randomized controlled trial (topic)
|
650 |
0 |
4 |
|a Randomized Controlled Trials as Topic
|
650 |
0 |
4 |
|a Research Design
|
650 |
0 |
4 |
|a survival
|
700 |
1 |
|
|a Cook, K.
|e author
|
700 |
1 |
|
|a Wang, R.
|e author
|
773 |
|
|
|t Biometrics
|